Linda Mileshkin (@Mileshkin / @anzgog)

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Linda Mileshkin to discuss the OUTBACK Trial. Dr. Mileshkin is the Deputy Director of Medical Oncology at the Peter MacCallum Cancer Centre and a board member of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG). She is a clinician researcher with a particular interest in gynaecological cancer and cancer of unknown primary (CUP).

Highlights

- Adjuvant chemotherapy with carboplatin and paclitaxel chemotherapy given after standard chemoradiation to women with locally advanced cervical cancer did not improve survival or relapse rates and should not be given.

- There is a major unmet need to improve outcomes and access to treatment for women with cervical cancer, as this is a major cause of death and suffering worldwide, most notably in LMICs.